Restricted accessResearch articleFirst published online 2009-03
In Vitro Differentiation of Adult Bone Marrow Progenitors into Antigen-Specific CD4 Helper T Cells Using Engineered Stromal Cells Expressing a Notch Ligand and a Major Histocompatibility Complex Class II Protein
A murine stromal cell line (OP9-DL1) expressing a notch ligand, Delta-like-1, has been shown to be able to drive the differentiation of both murine and human hematopoietic progenitors into T cells in vitro. Further studies showed that hematopoietic progenitors transduced by a retroviral vector to express a human CD8 T-cell receptor (TCR) followed by an OP9-DL1 monolayer coculture could generate antigen-specific cytotoxic T lymphocytes in vitro. It remains unknown if a similar method could be applied to produce CD4 helper T cells. In this report, we show that murine adult bone marrow (BM) cells transduced with an OT2 CD4 TCR and cocultured with OP9 stromal cells expressing Delta-like-1 can differentiate into antigen-specific CD4 T cells in vitro. These cells are capable of inducing the expression of T-cell activation markers and producing cytokines upon stimulation. We have also constructed a new stromal cell line (OP9-DL1-IAb) ectopically expressing a murine major histocompatibility complex class II protein, I-Ab, in OP9-DL1 cells. This new line could accelerate the development of TCR-transduced BM cells into CD4 T cells, resulting in cells with an improved capacity to respond to T-cell stimulation to secrete cytokines. Taken together, we demonstrate a general and potentially useful method to generate autologous antigen-specific CD4 helper T cells in vitro from easily accessible BM cells.
Get full access to this article
View all access options for this article.
References
1.
DouekDC, PickerLJ, KoupRA. 2003. T cell dynamics in HIV-1 infection. Annu Rev Immunol, 21:265–304.
2.
DudleyME, RosenbergSA. 2003. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer, 3:666–675.
3.
GattinoniL, PowellDJJr., RosenbergSA, RestifoNP. 2006. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol, 6:383–393.
RooneyCM, SmithCA, NgCY, LoftinSK, SixbeyJW, GanY, SrivastavaDK, BowmanLC, KranceRA, BrennerMK, HeslopHE. 1998. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 92:1549–1555.
7.
KhannaR, BellS, SherrittM, GalbraithA, BurrowsSR, RafterL, ClarkeB, SlaughterR, FalkMC, DouglassJ, WilliamsT, ElliottSL, MossDJ. 1999. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA, 96:10391–10396.
8.
CeredigR, JenkinsonEJ, MacDonaldHR, OwenJJ. 1982. Development of cytolytic T lymphocyte precursors in organ-cultured mouse embryonic thymus rudiments. J Exp Med, 155:617–622.
9.
SchmittTM, Zuniga-PfluckerJC. 2002. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity, 17:749–756.
10.
Zuniga-PfluckerJC. 2004. T-cell development made simple. Nat Rev Immunol, 4:67–72.
11.
de PooterR, Zuniga-PfluckerJC. 2007. T-cell potential and development in vitro: the OP9-DL1 approach. Curr Opin Immunol, 19:163–168.
12.
Wiktor-JedrzejczakW, BartocciA, FerranteAWJr., Ahmed-AnsariA, SellKW, PollardJW, StanleyER. 1990. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci USA, 87:4828–4832.
13.
YoshidaH, HayashiS, KunisadaT, OgawaM, NishikawaS, OkamuraH, SudoT, ShultzLD, NishikawaS. 1990. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature, 345:442–444.
14.
SchmittTM, de PooterRF, GronskiMA, ChoSK, OhashiPS, Zuniga-PfluckerJC. 2004. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat Immunol, 5:410–417.
15.
HuangJ, GarrettKP, PelayoR, Zuniga-PfluckerJC, PetrieHT, KincadePW. 2005. Propensity of adult lymphoid progenitors to progress to DN2/3 stage thymocytes with Notch receptor ligation. J Immunol, 175:4858–4865.
16.
La Motte-MohsRN, HererE, Zuniga-PfluckerJC. 2005. Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro. Blood, 105:1431–1439.
17.
De SmedtM, HoebekeI, PlumJ. 2004. Human bone marrow CD34+ progenitor cells mature to T cells on OP9-DL1 stromal cell line without thymus microenvironment. Blood Cells Mol Dis, 33:227–232.
18.
van LentAU, NagasawaM, van LoenenMM, SchotteR, SchumacherTN, HeemskerkMH, SpitsH, LegrandN. 2007. Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitors. J Immunol, 179:4959–4968.
19.
ZhaoY, ParkhurstMR, ZhengZ, CohenCJ, RileyJP, GattinoniL, RestifoNP, RosenbergSA, MorganRA. 2007. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res, 67:2425–2429.
20.
JanssenEM, LemmensEE, WolfeT, ChristenU, von HerrathMG, SchoenbergerSP. 2003. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature, 421:852–856.
21.
ShedlockDJ, ShenH. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science, 300:337–339.
22.
PardollDM, TopalianSL. 1998. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol, 10:588–594.
23.
Ostrand-RosenbergS. 2005. CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest, 23:413–419.
24.
ZouW. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol, 6:295–307.
25.
Van ParijsL, RefaeliY, LordJD, NelsonBH, AbbasAK, BaltimoreD. 1999. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity, 11:281–288.
26.
YangL, QinXF, BaltimoreD, Van ParijsL. 2002. Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells. Proc Natl Acad Sci USA, 99:6204–6209.
27.
BarndenMJ, AllisonJ, HeathWR, CarboneFR. 1998. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol, 76:34–40.
28.
BalciunaiteG, CeredigR, FehlingHJ, Zuniga-PfluckerJC, RolinkAG. 2005. The role of Notch and IL-7 signaling in early thymocyte proliferation and differentiation. Eur J Immunol, 35:1292–1300.
29.
ZakrzewskiJL, KochmanAA, LuSX, TerweyTH, KimTD, HubbardVM, MuriglanSJ, SuhD, SmithOM, GrubinJ, PatelN, ChowA, Cabrera-PerezJ, RadhakrishnanR, DiabA, PeralesMA, RizzutoG, MenetE, PamerEG, HellerG, Zuniga-PfluckerJC, AlpdoganO, van den BrinkMR. 2006. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med, 12:1039–1047.
30.
DouagiI, VieiraP, CumanoA. 2002. Lymphocyte commitment during embryonic development, in the mouse. Semin Immunol, 14:361–369.
31.
CromptonT, OutramSV, BucklandJ, OwenMJ. 1998. Distinct roles of the interleukin-7 receptor alpha chain in fetal and adult thymocyte development revealed by analysis of interleukin-7 receptor alpha-deficient mice. Eur J Immunol, 28:1859–1866.
32.
CarvalhoTL, Mota-SantosT, CumanoA, DemengeotJ, VieiraP. 2001. Arrested B lymphopoiesis and persistence of activated B cells in adult interleukin 7– mice. J Exp Med, 194:1141–1150.
33.
YangL, BaltimoreD. 2005. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc Natl Acad Sci USA, 102:4518–4523.
34.
PetrieHT, Zuniga-PfluckerJC. 2007. Zoned out: functional mapping of stromal signaling microenvironments in the thymus. Annu Rev Immunol, 25:649–679.
35.
GodfreyDI, ZlotnikA. 1993. Control points in early T-cell development. Immunol Today, 14:547–553.
36.
CeredigR, RolinkT. 2002. A positive look at double-negative thymocytes. Nat Rev Immunol, 2:888–897.
37.
BhandoolaA, von BoehmerH, PetrieHT, Zuniga-PfluckerJC. 2007. Commitment and developmental potential of extrathymic and intrathymic T cell precursors: plenty to choose from. Immunity, 26:678–689.
38.
NishimuraT, IwakabeK, SekimotoM, OhmiY, YahataT, NakuiM, SatoT, HabuS, TashiroH, SatoM, OhtaA. 1999. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med, 190:617–627.
39.
BaxevanisCN, VoutsasIF, TsitsilonisOE, GritzapisAD, SotiriadouR, PapamichailM. 2000. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol, 164:3902–3912.
40.
MarzoAL, KinnearBF, LakeRA, FrelingerJJ, CollinsEJ, RobinsonBW, ScottB. 2000. Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J Immunol, 165:6047–6055.
41.
MoellerM, HaynesNM, KershawMH, JacksonJT, TengMW, StreetSE, CeruttiL, JaneSM, TrapaniJA, SmythMJ, DarcyPK. 2005. Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. Blood, 106:2995–3003.
42.
von BoehmerH. 1990. Developmental biology of T cells in T cell-receptor transgenic mice. Annu Rev Immunol, 8:531–556.
43.
ArnoldPY, BurtonAR, VignaliDA. 2004. Diabetes incidence is unaltered in glutamate decarboxylase 65-specific TCR retrogenic nonobese diabetic mice: generation by retroviral-mediated stem cell gene transfer. J Immunol, 173:3103–3111.
44.
KesselsHW, WolkersMC, van den BoomMD, van der ValkMA, SchumacherTN. 2001. Immunotherapy through TCR gene transfer. Nat Immunol, 2:957–961.
45.
MorganRA, DudleyME, WunderlichJR, HughesMS, YangJC, SherryRM, RoyalRE, TopalianSL, KammulaUS, RestifoNP, ZhengZ, NahviA, de VriesCR, Rogers-FreezerLJ, MavroukakisSA, RosenbergSA. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314:126–129.
46.
HeemskerkMH, HagedoornRS, van der HoornMA, van der VekenLT, HoogeboomM, KesterMG, WillemzeR, FalkenburgJH. 2007. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood, 109:235–243.
47.
CohenCJ, ZhaoY, ZhengZ, RosenbergSA, MorganRA. 2006. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res, 66:8878–8886.
48.
KuballJ, DossettML, WolflM, HoWY, VossRH, FowlerC, GreenbergPD. 2007. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood, 109:2331–2338.
